Search results
Showing 51 to 100 of 1356 results for patients and public
This guideline covers how to assess and monitor body weight and how to prevent someone from becoming overweight or obese before, during and after pregnancy. The aim is to help all women who have a baby to achieve and maintain a healthy weight by adopting a balanced diet and being physically active.
This guideline covers assessing and managing faecal incontinence (any involuntary loss of faeces that is a social or hygienic problem) in people aged 18 and over. It aims to ensure that staff are aware that faecal incontinence is a sign or a symptom, not a diagnosis.
Sexually transmitted infections: condom distribution schemes (NG68)
This guideline covers condom distribution schemes. The aim is to reduce the risk of sexually transmitted infections (STIs). In addition, these schemes can provide a good introduction to broader sexual and reproductive health services, especially for younger people, and help prevent unplanned pregnancies.
In development [GID-TA11450] Expected publication date: 16 October 2024
In development [GID-TA11409] Expected publication date: 29 January 2025
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
In development [GID-TA10992] Expected publication date: 15 May 2024
This guideline covers road-traffic-related air pollution and its links to ill health. It aims to improve air quality and so prevent a range of health conditions and deaths.
HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)
This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.
In development [GID-TA11480] Expected publication date: 13 November 2024
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
In development [GID-TA11436] Expected publication date: 11 December 2024
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
In development [GID-TA11423] Expected publication date: 11 December 2024
In development [GID-TA11348] Expected publication date: TBC
Coexisting severe mental illness and substance misuse (QS188)
This quality standard covers the assessment, management and care provided for people aged 14 and over who have coexisting severe mental illness and substance misuse. It describes high-quality care in priority areas for improvement.
This quality standard covers providing and organising services for people with sarcoma. It includes pathways for referral and diagnosis, treatment and support for adults, young people and children with sarcoma. It describes high-quality care in priority areas for improvement.
View quality statements for QS78Show all sections
Sections for QS78
- Introduction
- List of quality statements
- Quality statement 1: Diagnostic pathways
- Quality statement 2: Multidisciplinary teams for sarcoma
- Quality statement 3: Publishing information about areas of expertise
- Quality statement 4: Retroperitoneal sarcoma
- Quality statement 5: Surgical skills
- Quality statement 6: Key workers
In development [GID-TA11512] Expected publication date: TBC
In development [GID-TA11351] Expected publication date: TBC
In development [GID-TA11352] Expected publication date: 26 February 2025
In development [GID-TA11364] Expected publication date: TBC
Safe staffing for nursing in adult inpatient wards in acute hospitals (SG1)
This guideline covers organisational and managerial approaches to safe nurse staffing of inpatient wards for people aged 18 and over in acute hospitals. It aims to ensure that patients receive the nursing care they need, regardless of the ward to which they are allocated, the time of the day, or the day of the week.
In development [GID-TA11471] Expected publication date: 05 June 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
In development [GID-TA11062] Expected publication date: 16 October 2024
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]
In development [GID-TA11148] Expected publication date: 14 August 2024
In development [GID-TA11220] Expected publication date: 17 July 2024
Fruquintinib for previously treated metastatic colorectal cancer ID6274
In development [GID-TA11280] Expected publication date: 18 September 2024
This guideline covers preventing, identifying and managing latent and active tuberculosis (TB) in children, young people and adults. It aims to improve ways of finding people who have TB in the community and recommends that everyone under 65 with latent TB should be treated. It describes how TB services should be organised, including the role of the TB control board.
Somapacitan for treating growth hormone deficiency in children [ID6178]
In development [GID-TA11153] Expected publication date: TBC
This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.
In development [GID-TA11221] Expected publication date: 11 September 2024
Relugolix for treating hormone-sensitive prostate cancer [ID6187]
In development [GID-TA11141] Expected publication date: TBC
In development [GID-TA11370] Expected publication date: 16 October 2024
In development [GID-TA11371] Expected publication date: 11 September 2024
Elafibranor for treating primary biliary cholangitis [ID6331]
In development [GID-TA11378] Expected publication date: TBC
Awaiting development [GID-TA11398] Expected publication date: 13 November 2024
In development [GID-TA10948] Expected publication date: 26 June 2024
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
In development [GID-TA10733] Expected publication date: TBC
In development [GID-TA11090] Expected publication date: TBC
In development [GID-HST10054] Expected publication date: TBC
In development [GID-TA11384] Expected publication date: 13 November 2024
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
In development [GID-TA11389] Expected publication date: 12 June 2024
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: 14 August 2024
In development [GID-TA10883] Expected publication date: 18 September 2024
In development [GID-HST10059] Expected publication date: 18 December 2024
In development [GID-TA11263] Expected publication date: TBC
Awaiting development [GID-TA10165] Expected publication date: TBC
In development [GID-TA11359] Expected publication date: 11 December 2024
This quality standard covers care after emergency treatment for suspected anaphylaxis, including assessment and referral to specialist allergy services. It describes high-quality care in priority areas for improvement.
View quality statements for QS119Show all sections
Sections for QS119
- Quality statements
- Quality statement 1: Referral to specialist allergy services after emergency treatment
- Quality statement 2: Education in adrenaline auto-injector use
- Quality statement 3: Specialist assessment for venom immunotherapy
- Quality statement 4 (placeholder): Ongoing training in adrenaline auto-injector use
- Update information
- About this quality standard
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]
In development [GID-TA11132] Expected publication date: 26 June 2024
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
In development [GID-TA11391] Expected publication date: 23 October 2024
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
In development [GID-TA11117] Expected publication date: 14 August 2024